In current (mostly phase I) trials in lung cancer, the CAR-T cell’s extracellular single-chain variable fragment (scFv) has been engineered to bind to TAA ligand targets such as CEA, MUC1, or EGFR in NSCLC trials, and DLL3 in SCLC, using mostly autologous cell preparations (88). This evidence concerns the gene DLL3 and small cell lung carcinoma.